Wang SC, Yang WY. Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports. World J Clin Cases 2021; 9(1): 204-210 [PMID: 33511186 DOI: 10.12998/wjcc.v9.i1.204]
Corresponding Author of This Article
Wen-Yu Yang, PhD, Chief Doctor, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 288 Nanjing Road, Tianjin 300020, China. yangwenyu@ihcams.ac.cn
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 6, 2021; 9(1): 204-210 Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.204
Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports
Shi-Chong Wang, Wen-Yu Yang
Shi-Chong Wang, Wen-Yu Yang, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
Author contributions: Wang SC collected the data and wrote the manuscript; Yang WY revised the manuscript for important intellectual content and English language; All authors approved the final version of the manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Yu Yang, PhD, Chief Doctor, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 288 Nanjing Road, Tianjin 300020, China. yangwenyu@ihcams.ac.cn
Received: June 24, 2020 Peer-review started: June 24, 2020 First decision: October 18, 2020 Revised: October 22, 2020 Accepted: November 12, 2020 Article in press: November 12, 2020 Published online: January 6, 2021 Processing time: 190 Days and 21.9 Hours
Core Tip
Core Tip: In the present report, we describe 2 pediatric patients diagnosed as myeloid neoplasm (MN) with eosinophilia and platelet-derived growth factor receptor beta (PDGFRB) rearrangement and reviewed the relative literature to analyze the clinical and therapeutic features of this rare clinical entity. Although MN with PDGFRB rearrangement rarely occurs in children, awareness should be increased for the possibility of this disease. Detection of the mutant gene by fluorescence in situ hybridization is necessary once the disease is suspected. Imatinib had a considerable effect on children, though the dose of imatinib is still unclear. Moreover, additional attention should be paid regarding the prognosis, life expectancy, side effects, and quality of life of these pediatric patients.
